JP2019017385A - ヒトarcapトランスジェニックマウス - Google Patents
ヒトarcapトランスジェニックマウス Download PDFInfo
- Publication number
- JP2019017385A JP2019017385A JP2018128797A JP2018128797A JP2019017385A JP 2019017385 A JP2019017385 A JP 2019017385A JP 2018128797 A JP2018128797 A JP 2018128797A JP 2018128797 A JP2018128797 A JP 2018128797A JP 2019017385 A JP2019017385 A JP 2019017385A
- Authority
- JP
- Japan
- Prior art keywords
- human
- liver
- arcap
- transgenic animal
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000917420 Homo sapiens DDB1- and CUL4-associated factor 6 Proteins 0.000 title claims abstract description 75
- 102100029587 DDB1- and CUL4-associated factor 6 Human genes 0.000 title claims abstract description 70
- 238000011830 transgenic mouse model Methods 0.000 title claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 210000004185 liver Anatomy 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 32
- 230000009261 transgenic effect Effects 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 239000002299 complementary DNA Substances 0.000 claims abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 13
- 210000000952 spleen Anatomy 0.000 claims abstract description 13
- 210000001015 abdomen Anatomy 0.000 claims abstract description 11
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 8
- 241000699670 Mus sp. Species 0.000 claims abstract description 7
- 239000013598 vector Substances 0.000 claims abstract description 5
- 241001529936 Murinae Species 0.000 claims description 16
- 241000699660 Mus musculus Species 0.000 claims description 14
- 108010088751 Albumins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 10
- 210000002751 lymph Anatomy 0.000 claims description 10
- 210000000287 oocyte Anatomy 0.000 claims description 6
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims description 5
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 3
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 claims description 3
- 102000046818 human AR Human genes 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000520 microinjection Methods 0.000 abstract description 6
- 210000002380 oogonia Anatomy 0.000 abstract 2
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010019695 Hepatic neoplasm Diseases 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 208000021550 spleen neoplasm Diseases 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102100021869 Tyrosine aminotransferase Human genes 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 1
- 108010042606 Tyrosine transaminase Proteins 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
【解決手段】肝臓特異的プロモーターに作動可能に連結されたヒトARCAPをコードする核酸をそのゲノム中に含む、非ヒトトランスジェニック動物。該トランスジェニック動物は、ヒトARCAPタンパク質を発現し、肝臓、脾臓、腹部、又はリンパの腫瘍を発生する。また、ヒトARCAP遺伝子を発現する非ヒトトランスジェニック動物に由来する細胞株も提供される。さらに、肝臓特異的プロモーターに作動可能に連結されたヒトARCAP cDNAを含むベクターを受精したマウス卵母細胞にマイクロインジェクションし、マイクロインジェクションを行った該マウス卵母細胞を里親マウスに移植することによって、トランスジェニックマウスを産生する方法が提供される。
【選択図】なし
Description
組織におけるヒトARCAP mRNAの発現を評価するためにノーザンブロット分析を行った。結果を図1Aに示す。ヒトARCAP mRNAは、心臓及び骨格筋において弱く発現される。ヒトARCAP mRNAは、正常な肝臓組織を含む大半の正常なヒト組織では発現されない。
正常な肝臓細胞の永久的トランスフェクション
2.8kbの全長ヒトARCAP cDNAをベクターpLXSNへクローニングし、それを使用して正常なネズミ肝臓BNL細胞をトランスフェクトした。簡潔には、BNL細胞を10%CO2中、37℃で増殖させた。Lipofectamine 2000及び培地と混合されたプラスミドDNAコンストラクトを、60%〜70%のコンフルエンスに達する際に細胞に添加した。24時間後、培地を新鮮培地と交換した。安定な形質移入体を選択するため、ジェネテシン(Geneticin)(G418)を培地に添加した。BNL細胞をpLXSN−ARCAPでトランスフェクトし、G418で選択することで、ヒトARCAPを過剰発現する永久的にトランスフェクトされた細胞(BNL−ARCAP)を樹立した。対照細胞を空のプラスミドpLXSNでトランスフェクトし、選択に供してBNL−pLXSN細胞を作出した。BNL細胞におけるヒトARCAPの発現を、細胞遊走、細胞侵入、及び足場非依存性クローン増殖に対するその効果について評価した。
組織培養表面上での細胞遊走速度を測定するため、in vitro創傷治癒アッセイを使用した。このアッセイは、in vivoでの創傷治癒の間の細胞遊走を模倣するものである。このアッセイは、細胞遊走に対する細胞−マトリクス及び細胞−細胞の相互作用の効果に関する研究に特に適している。
ポリ−L−リジンで上部のトランスウェルを覆うことにより、トランスウェル組織培養チャンバーを用意した。BNL細胞、BNL−pLXSN細胞、及びBNL−ARCAP細胞を、1ウェル当たり1×105細胞の細胞密度で別々の上部トランスウェルに蒔いた。トランスウェルチャンバーを、10%CO2中、37℃でインキュベートした。
軟寒天コロニー形成アッセイを使用して、in vitroでの足場非依存性細胞増殖を定量する。細胞の足場非依存性増殖は、それらの細胞の腫瘍化の可能性と相関する。
標準的な技術を使用して、2.8kbの全長ヒトARCAP cDNAをマウスアルブミンプロモーターの下流の発現ベクターにサブクローニングした。図2Aを参照されたい。得られた5.8kbのアルブミンプロモーター/ARCAPコンストラクトを、マイクロインジェクションに先立ってNot I及びSap Iで消化した。
台湾動物センター(台湾、台北)において、受精したC57/BL6Jの雌性胎仔(0.5dpcの胎仔)にARCAPを含むDNAをマイクロインジェクションした。注入された接合子は、標準プロトコルに従って雌里親マウスに戻した。トランスジェニックマウスを、標準的な特定病原体除去条件下で作製し、収容した。台北栄民総医院の動物施設の研究所において、動物実験委員会によって設立された規則に従い、全ての動物研究を行った。
アルブミンプロモーターからヒトARCAPを発現する20匹のトランスジェニックマウス、及びアルブミンプロモーターからヒトARCAPを発現する20匹のマウスを分析した。40匹全てのマウスが、出生から3か月以内に腫瘍を発生した。
本明細書に開示される特徴の全ては、任意の組み合せで合わせられ得る。本明細書で開示されるそれぞれの特徴は、同一の、等価の、又は類似する目的を果たす代替的な特徴で置換され得る。したがって、特に明記されない限り、開示されるそれぞれの特徴は、総括的な一連の等価又は同様の特徴の例に過ぎない。
Claims (17)
- 非ヒトトランスジェニック動物であって、肝臓特異的プロモーターに作動可能に連結されたヒトアンドロゲン受容体複合体関連タンパク質(ARCAP)をコードする核酸をそのゲノム中に含み、前記トランスジェニック動物が、ヒトARCAPタンパク質を発現し、肝臓、脾臓、腹部、又はリンパの腫瘍を発生する、非ヒトトランスジェニック動物。
- 哺乳動物である、請求項1に記載の非ヒトトランスジェニック動物。
- 前記哺乳動物が霊長類、有蹄類、イヌ、ネズミ、又はネコである、請求項2に記載の非ヒトトランスジェニック動物。
- 前記哺乳動物がマウスである、請求項3の非ヒトトランスジェニック動物。
- 前記肝臓特異的プロモーターが、アルブミンプロモーター、又はホスホエノールピルビン酸カルボキシキナーゼ(PEPCK)プロモーターである、請求項1に記載の非ヒトトランスジェニック動物。
- 前記肝臓特異的プロモーターが、ネズミアルブミンプロモーター、又はネズミホスホエノールピルビン酸カルボキシキナーゼ(PEPCK)プロモーターである、請求項4に記載の非ヒトトランスジェニック動物。
- 前記核酸が配列番号1の配列を含む、請求項4に記載の非ヒトトランスジェニック動物。
- 前記核酸が配列番号1の配列を含む、請求項6に記載の非ヒトトランスジェニック動物。
- 請求項1に記載の非ヒトトランスジェニック動物に由来する細胞株。
- 前記細胞株が、肝臓、脾臓、腹部、又はリンパの腫瘍に由来する、請求項9に記載の細胞株。
- 請求項4に記載の非ヒトトランスジェニック動物に由来する細胞株。
- 前記細胞株が、肝臓、脾臓、腹部、又はリンパの腫瘍に由来する細胞株である、請求項11に記載の細胞株。
- 請求項6に記載の非ヒトトランスジェニック動物に由来する細胞株。
- 前記細胞株が、肝臓、脾臓、腹部、又はリンパの腫瘍に由来する、請求項13に記載の細胞株。
- トランスジェニックマウスを産生する方法であって、
受精したマウス卵母細胞に、肝臓特異的プロモーターに作動可能に連結されたヒトアンドロゲン受容体複合体関連タンパク質(ARCAP)cDNAを含むベクターをマイクロインジェクションすることと、
マイクロインジェクションを行ったマウス卵母細胞を里親マウスに移植し、それによってヒトARCAPを発現するトランスジェニックマウスを産生することと、
を含み、
前記トランスジェニックマウスが肝臓、脾臓、腹部、又はリンパの腫瘍を発生する、方法。 - 前記肝臓特異的プロモーターが、ネズミアルブミンプロモーター、又はネズミホスホエノールピルビン酸カルボキシキナーゼ(PEPCK)プロモーターである、請求項15に記載の方法。
- 前記cDNAが配列番号1の配列を含む、請求項16に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/650,073 | 2017-07-14 | ||
US15/650,073 US10349638B2 (en) | 2017-07-14 | 2017-07-14 | Human ARCAP transgenic mouse |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019017385A true JP2019017385A (ja) | 2019-02-07 |
Family
ID=63012805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018128797A Pending JP2019017385A (ja) | 2017-07-14 | 2018-07-06 | ヒトarcapトランスジェニックマウス |
Country Status (5)
Country | Link |
---|---|
US (1) | US10349638B2 (ja) |
EP (1) | EP3427580B1 (ja) |
JP (1) | JP2019017385A (ja) |
CN (1) | CN109247302A (ja) |
TW (1) | TW201907801A (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002262871A (ja) * | 2001-02-28 | 2002-09-17 | Veterans General Hospital | アンドロゲン受容体複合体結合タンパク質 |
US20030054438A1 (en) * | 2001-01-17 | 2003-03-20 | Tai-Jay Chang | Androgen receptor complex-associated protein |
US20030082721A1 (en) * | 2001-01-17 | 2003-05-01 | Tai-Jay Chang | Transgenic animals expressing androgen receptor complex-associated protein |
JP2004065202A (ja) * | 2002-08-09 | 2004-03-04 | Taipei Veterans General Hospital | アンドロゲン受容体複合体結合性タンパク質を発現するトランスジェニック動物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5907078A (en) * | 1994-12-09 | 1999-05-25 | Greenberg; Norman M. | Transgenic mouse model for prostate cancer |
US6891028B1 (en) | 1998-11-06 | 2005-05-10 | Cedars-Sinai Medical Center | Nucleic acids encoding transferrin receptor-like proteins |
US20030099976A1 (en) * | 2001-01-17 | 2003-05-29 | Tai-Jay Chang | Androgen receptor complex-associated protein |
EP1534064A4 (en) * | 2002-07-17 | 2008-01-23 | Bristol Myers Squibb Co | TRANSGENIC NON-MENTAL ANIMALS EXPRESSING A REPORTERNUCLEIC ACID UNDER REGULATION THROUGH ANDROGEN RECEPTOR TARGET SEQUENCES |
US7655700B2 (en) * | 2005-08-25 | 2010-02-02 | Michigan State University | Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
-
2017
- 2017-07-14 US US15/650,073 patent/US10349638B2/en not_active Expired - Fee Related
-
2018
- 2018-07-06 JP JP2018128797A patent/JP2019017385A/ja active Pending
- 2018-07-13 EP EP18183472.2A patent/EP3427580B1/en active Active
- 2018-07-13 CN CN201810768992.0A patent/CN109247302A/zh active Pending
- 2018-07-13 TW TW107124297A patent/TW201907801A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030054438A1 (en) * | 2001-01-17 | 2003-03-20 | Tai-Jay Chang | Androgen receptor complex-associated protein |
US20030082721A1 (en) * | 2001-01-17 | 2003-05-01 | Tai-Jay Chang | Transgenic animals expressing androgen receptor complex-associated protein |
JP2002262871A (ja) * | 2001-02-28 | 2002-09-17 | Veterans General Hospital | アンドロゲン受容体複合体結合タンパク質 |
JP2004065202A (ja) * | 2002-08-09 | 2004-03-04 | Taipei Veterans General Hospital | アンドロゲン受容体複合体結合性タンパク質を発現するトランスジェニック動物 |
Also Published As
Publication number | Publication date |
---|---|
CN109247302A (zh) | 2019-01-22 |
EP3427580B1 (en) | 2021-03-03 |
US20190014756A1 (en) | 2019-01-17 |
US10349638B2 (en) | 2019-07-16 |
EP3427580A1 (en) | 2019-01-16 |
TW201907801A (zh) | 2019-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thoms et al. | ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer | |
EP0516664B1 (en) | Transgenic animals, cells and cell lines therefrom, and their use | |
Inoue et al. | A mouse line expressing Sall1‐driven inducible Cre recombinase in the kidney mesenchyme | |
Puech et al. | Normal cardiovascular development in mice deficient for 16 genes in 550 kb of the velocardiofacial/DiGeorge syndrome region | |
IE83909B1 (en) | Transgenic animals, cells and cell lines therefrom, and their use | |
JP2008263987A (ja) | 遺伝子の同定および特徴付け | |
JP2008102012A (ja) | 癌幹細胞の同定および単離方法 | |
Huijbers et al. | An inducible mouse model of melanoma expressing a defined tumor antigen | |
Mo et al. | Gene deletion in urothelium by specific expression of Cre recombinase | |
CN105039402B (zh) | 一种改良猪肌肉品质的方法 | |
AU2004268639B2 (en) | Chimeric cancer models | |
CN102747096A (zh) | 基因搜寻载体、随机基因突变调控方法及用途 | |
JP2019017385A (ja) | ヒトarcapトランスジェニックマウス | |
CN109970849A (zh) | zkscan3基因或其蛋白抑制剂在肿瘤治疗中的应用 | |
JP5058336B2 (ja) | Sld5を高発現するがん幹細胞 | |
KR102133179B1 (ko) | Irx1 유전자-녹아웃 형질전환 제브라피쉬 모델 및 이의 용도 | |
Lebel et al. | Transgenic mice bearing the polyomavirus large T antigen directed by 2.1 kb of the keratin 19 promoter develop bronchiolar papillary tumors with progression to lung adenocarcinomas | |
Harsin | Characterization of the principal and secondary islets during pancreatic development in zebrafish with a CRISPR-mediated Glis3 knockout | |
Meenu et al. | Alternative Animal Models in Cancer Research | |
JP4017544B2 (ja) | 精子増殖方法 | |
Licence et al. | The VpreB1 enhancer drives developmental stage‐specific gene expression in vivo | |
van Valckenborgh | Salivary and mammary gland tumorigenesis in PLAG1 transgenic mice | |
JPH0779773A (ja) | 癌細胞株 | |
SchneidER-MAUNOURY¹ et al. | TANIA SEITANIDOU¹, GIOVANNI LEVI12, PAULA MURPHY'AND PATRICK CHARNAY! | |
Martino et al. | Innovative strategies for improving engineered mouse models of human cancer for preclinical development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180817 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200721 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220111 |